(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 13.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Karyopharm Therapeutics's revenue in 2026 is $151,118,000.On average, 9 Wall Street analysts forecast KPTI's revenue for 2026 to be $3,092,585,202, with the lowest KPTI revenue forecast at $2,749,468,245, and the highest KPTI revenue forecast at $3,306,523,384. On average, 8 Wall Street analysts forecast KPTI's revenue for 2027 to be $3,590,036,801, with the lowest KPTI revenue forecast at $2,685,105,487, and the highest KPTI revenue forecast at $4,557,064,578.
In 2028, KPTI is forecast to generate $5,317,406,316 in revenue, with the lowest revenue forecast at $4,610,775,753 and the highest revenue forecast at $6,365,567,430.